The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Bone biomarkers and overall survival (OS) in men with advanced hormone-sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of ADT +/- orteronel.
 
Primo "Lucky" N. Lara
Consulting or Advisory Role - Calithera Biosciences (Inst); Janssen
Research Funding - Janssen Biotech (Inst); Taiho Pharmaceutical (Inst)
 
Edward Mayerson
No Relationships to Disclose
 
Erik Gertz
No Relationships to Disclose
 
Catherine Tangen
No Relationships to Disclose
 
Amir Goldkorn
Research Funding - Menarini Silicon Biosystems; RareCyte; Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - I am listed as a co-inventor on a patent held jointly by USC and Caltech for a microfilter we developed for capturing live circulating tumor cells from blood.
 
Marta Van Loan
No Relationships to Disclose
 
Maha H. A. Hussain
Honoraria - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; Merck; OncLive; Precisca; Research to Practice; UroToday; UroToday
Consulting or Advisory Role - Bayer; BMS; Janssen; Merck; Novartis; Pfizer; Tempus
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
 
Shilpa Gupta
Stock and Other Ownership Interests - Moderna Therapeutics; Nektar
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - AVEO; EMD Serono; Gilead Sciences; Guardant Health; Loxo/Lilly; Merck; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Janssen Oncology
 
Jingsong Zhang
Honoraria - AstraZeneca/MedImmune; Bayer; Dendreon; EMD Serono; Pfizer; Sanofi; Sanofi/Aventis; Seagen
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Dendreon; EMD Serono; Pfizer
Speakers' Bureau - AstraZeneca; Dendreon; Sanofi; Seagen
 
Mamta Parikh
Consulting or Advisory Role - AstraZeneca; Exelixis; OncoCyte; Seagen
Research Funding - Karyopharm Therapeutics
 
Przemyslaw Twardowski
Honoraria - Astellas Medivation; AstraZeneca; AVEO; AVEO; Bayer; Genentech/Roche; Janssen; Pfizer; Sanofi/Aventis
Consulting or Advisory Role - AstraZeneca; Janssen; Sanofi/Aventis
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen; Sanofi
 
David I. Quinn
Employment - Abbvie
Honoraria - AVEO; Bayer; Bristol-Myers Squibb; Clinigen Group; Exelixis; Genentech/Roche; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Seagen
Consulting or Advisory Role - AVEO; Bayer; Bristol-Myers Squibb; Clinigen Group; Eisai; Exelixis; Genentech/Roche; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Seagen; US Biotest
Research Funding - Genentech/Roche (Inst); Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Merck; Roche
(OPTIONAL) Uncompensated Relationships - Eisai; US Biotest
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Merck; Novartis; Pfizer; UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Caris Life Sciences; Clovis Oncology; Corvus Pharmaceuticals; Eisai; Genentech/Roche; Janssen Oncology; Merck; Modra Pharmaceuticals; Myovant Sciences; on quality; Pfizer; Tolero Pharmaceuticals
Speakers' Bureau - AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Myovant Sciences; Sanofi; Seattle Genetics/Astellas
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst)
Expert Testimony - Novartis
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; Sanofi/Aventis; US Oncology
 
Ian M Thompson
Consulting or Advisory Role - Magforce; Profound Medical
Research Funding - MagForce
Patents, Royalties, Other Intellectual Property - I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation Medicine; Genentech; Gilead Sciences; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)